GSK has begun the sale of some of its consumer health brands, hoping to raise around £1 billion before spinning off its consumer healthcare business, according to reports.

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

The manufacturer, GSK, was going to stop manufacturing the brand-name medication in 2024 ... The FTC and others argued that ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

GSK GSK1.94%increase; green up pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Nigeria, the giant of Africa, has recently experienced a great downturn in its economy, leading to the exodus of several ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...

Haleon, the two-year-old CPG spinoff from GSK, is not only leading ... to Haleon’s pain relief brands, SeeMe also cited Kenvue’s Tylenol for prioritizing consumer wellness “through ...